MD Anderson researchers present new findings in targeted and combination therapies at 2021 ASCO Annual Meeting

(University of Texas M. D. Anderson Cancer Center) Several Phase II clinical trials conducted by researchers from The University of Texas MD Anderson Cancer Center show promising results for patients with melanoma, breast cancer, HER2-positive tumors and ovarian cancer. The results of these studies, which will be presented at the virtual 2021 American Society of Clinical Oncology (ASCO) Annual Meeting, highlight new advances in drug therapy research to improve patient outcomes.